# A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)

> **NCT06548100** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 9 (actual)

## Conditions studied

- Generalized Lipodystrophy

## Interventions

- **DRUG:** mibavademab

## Key facts

- **NCT ID:** NCT06548100
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-12-16
- **Primary completion:** 2026-07-14
- **Final completion:** 2026-11-03
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06548100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06548100, "A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06548100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*